Bismuth-Based Quadruple Therapy versus Metronidazole-Intensified Triple Therapy as a First-Line Treatment for Clarithromycin-Resistant <i>Helicobacter pylori</i> Infection: A Multicenter Randomized Controlled Trial.
Seung In SeoHyun LimChang-Seok BangYoung Joo YangGwang Ho BaikSang Pyo LeeHyun Joo JangSea Hyub KaeJinseob KimHak Yang KimWoon Geon ShinPublished in: Gut and liver (2022)
Fourteen-day bismuth-based quadruple therapy showed comparable efficacy with 14-day metronidazole-intensified triple therapy, and it was more cost-effective in the context of clarithromycin-resistant <i>H. pylori</i> infection.